Our top pick for
Achieve Life Sciences, Inc is a biotechnology business based in the US. Achieve Life Sciences shares (ACHV) are listed on the NASDAQ and all prices are listed in US Dollars. Achieve Life Sciences employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$6.60 - $18.26|
|50-day moving average||$11.31|
|200-day moving average||$10.29|
|Wall St. target price||$45.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.61|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-30.04%|
|Return on equity TTM||-53.24%|
|Market capitalisation||$66.4 million|
TTM: trailing 12 months
There are currently 468,643 Achieve Life Sciences shares held short by investors – that's known as Achieve Life Sciences's "short interest". This figure is 2.1% up from 458,921 last month.
There are a few different ways that this level of interest in shorting Achieve Life Sciences shares can be evaluated.
Achieve Life Sciences's "short interest ratio" (SIR) is the quantity of Achieve Life Sciences shares currently shorted divided by the average quantity of Achieve Life Sciences shares traded daily (recently around 73570.32967033). Achieve Life Sciences's SIR currently stands at 6.37. In other words for every 100,000 Achieve Life Sciences shares traded daily on the market, roughly 6370 shares are currently held short.
However Achieve Life Sciences's short interest can also be evaluated against the total number of Achieve Life Sciences shares, or, against the total number of tradable Achieve Life Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Achieve Life Sciences's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Achieve Life Sciences shares in existence, roughly 80 shares are currently held short) or 0.0764% of the tradable shares (for every 100,000 tradable Achieve Life Sciences shares, roughly 76 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Achieve Life Sciences.
Find out more about how you can short Achieve Life Sciences stock.
We're not expecting Achieve Life Sciences to pay a dividend over the next 12 months.
Achieve Life Sciences's shares were split on a 1:20 basis on 30 July 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Achieve Life Sciences shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Achieve Life Sciences shares which in turn could have impacted Achieve Life Sciences's share price.
Over the last 12 months, Achieve Life Sciences's shares have ranged in value from as little as $6.6 up to $18.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Achieve Life Sciences's is 1.2897. This would suggest that Achieve Life Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Achieve Life Sciences, Inc. , a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.